Press Releases

May 8, 2019 at 8:00 AM EDT
Altimmune to Announce First Quarter 2019 Financial Results on May 15
GAITHERSBURG, Md. , May 08, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the first quarter ended March 31, 2019 before the market open and host a conference call on Wednesday, May 15,
March 21, 2019 at 4:15 PM EDT
Altimmune to Announce Year End 2018 Financial Results on April 2
GAITHERSBURG, Md. , March 21, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the year ended December 31, 2018 before the market open and host a conference call on Tuesday, April 2, 2019
March 19, 2019 at 7:00 AM EDT
Altimmune Announces Positive Results from NasoVAX Extension Study
Seroprotective HAI antibody response persisted more than one year after vaccination Company seeking partnership for further development and commercialization of NasoVAX GAITHERSBURG, Md. , March 19, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company,
March 14, 2019 at 9:00 AM EDT
Altimmune to Participate at 31st Annual ROTH Conference
GAITHERSBURG, Md. , March 14, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, announced today that Vipin K. Garg , Ph.D., President and Chief Executive Officer, and Will Brown , Acting Chief Financial Officer, will provide a corporate overview at
March 12, 2019 at 1:34 PM EDT
Altimmune Announces Closing of $14 Million Registered Direct Offering
GAITHERSBURG, Md. , March 12, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced the closing of the previously announced registered direct offering of common units and pre-funded units receiving gross proceeds of $14 million .
March 8, 2019 at 9:29 AM EST
Altimmune Announces $14 million Registered Direct Offering
GAITHERSBURG, Md. , March 08, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced it has entered into a purchase agreement with two institutional investors for the purchase of common units and pre-funded units for a combined total of
Displaying 11 - 20 of 21

Investor Contact

Ashley Robinson
LifeSci Advisors, LLC

Email: arr@lifesciadvisors.com

Email Alerts

Automatically receive Altimmune, Inc. financial information by e-mail

Subscribe